Skip to main content

Table 2 Background information at time of interview (n = 11 children)

From: Impact of the COVID-19 pandemic on access to the cerliponase alfa managed access agreement in England for CLN2 treatment

 

Mean ± SD

Range

Time on treatment (months)

23.1 ± 24.7

0.0–76.0

Time on MAA (months)

7.1 ± 4.6

0.0–12.0

Age (months)

106.5 ± 54.6

50.0–224.0

Distance travelled by families (km)a

209.5 ± 110.6

6.5–398.0

  1. MAA managed access agreement
  2. an = 9 families
Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172